Startell Bioceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
as on 03-07-2024
- Paid Up Capital ₹ 3.50 M
as on 03-07-2024
- Company Age 8 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.70 M
as on 03-07-2024
- Revenue 31.93%
(FY 2023)
- Profit 109.16%
(FY 2023)
- Ebitda 136.86%
(FY 2023)
- Net Worth 2.22%
(FY 2023)
- Total Assets 12.52%
(FY 2023)
About Startell Bioceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 3.50 M.
The company currently has active open charges totaling ₹6.70 M.
Bijal Desai and Santosh Dube serve as directors at the Company.
- CIN/LLPIN
U52394MH2016PTC280155
- Company No.
280155
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 Apr 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Majiwada, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Startell Bioceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bijal Desai  | Director | 25-Apr-2016 | Current |
| Santosh Dube | Director | 25-Apr-2016 | Current |
Financial Performance and Corporate Structure Insights of Startell Bioceuticals.
Startell Bioceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 31.93% increase. The company also saw a substantial improvement in profitability, with a 109.16% increase in profit. The company's net worth moved up by a moderate rise of 2.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Startell Bioceuticals?
In 2023, Startell Bioceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Holden Medical Laboratories Private LimitedActive 29 years 10 monthsSantosh Dube is a mutual person
Startell Medical Management Services LlpActive 3 years 5 monthsBijal Desai and Santosh Dube are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 02 Aug 2019 | ₹6.70 M | Open |
How Many Employees Work at Startell Bioceuticals?
Startell Bioceuticals has a workforce of 58 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Startell Bioceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Startell Bioceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
